Monoterpenes reduced adducts formation in rats exposed to aflatoxin B 1

African Journal of Biotechnology

Volumn 1, Issue 2, 2002, Pages 29-36

  Elegbede, J Abiodun ^a   Gould, Michael N ^b  

^a UNIVERSITY OF NEVADA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Aflatoxin B1; Chemoprevention; Hepatocarcinogenesis; Monoterpenes

Indexed keywords

AFLATOXIN B1; ANTINEOPLASTIC AGENT; LIMONENE; PERILLYL ALCOHOL; TERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; BREAST TUMOR; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA ADDUCT; LIVER; LIVER CANCER; LIVER CARCINOGENESIS; MALE; NONHUMAN; RAT;

ANIMALIA;

EID: 3242666829     PISSN: 16845315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bolton MG, Munoz A, Jacobson LP, Groopman JD, Maxuitenko YY, Roebuck BD, Kensler TW (1993). Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. Cancer Res. 53:3499-3504. [PubMed]
2. Chapot B, Wild CP (1991). ELISA for quantification of aflatoxin-albumin adducts and their application to human exposure assessment. Technol. Diagnostic Pathol. 2:135-155.
3. Coles B, Meyer DJ, Ketterer B, Stanton CA, Garner RC (1985). Studies on the detoxication of microsomally-activated aflatoxin B1 by glutathione and glutathione transferases in vitro. Carcinogenesis 6:693-697. [PubMed]
4. Crowell PL (1999). Prevention and therapy of cancer by dietary monoterpenes. J. Nutr. 129:775S-778S. [PubMed]
5. Egner PA, Wang JB, Zhu YR, Zhang BC, Wu Y, Zhang QN, Qian GS, Kuang SY, Gange SJ, Jacobson LP, Helzlsouer KJ, Bailey GS, Groopman JD, Kensler TW (2001). Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc. Natl. Acad. Sci. USA 98:14601-14606. [PubMed]
6. Elegbede JA, Elson CE, Tanner MA, Qureshi A, Gould MN (1986). Regression of rat primary mammary tumors following dietary d-limonene. J. Natl. Cancer Inst. 76:323-325. [PubMed]
7. Elegbede JA, Maltzman TH, Elson CE, Gould MN (1993). Effects of anticarcinogenic monoterpenes on phase II hepatic metabolizing enzymes. Carcinogenesis 14:1221-1223. [PubMed]
8. 7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats. Carcinogenesis 13:101-106. [PubMed]
9. Groopman JD, Wogan GN, Roebuck BD, Kensler TW (1994). Molecular biomarkers for aflatoxins and their application to human cancer prevention. Cancer Res. 54:1907s-1911s. [PubMed]
10. Haag JD, Lindstrom MJ, Gould MN (1992). Limonene-induced regression of mammary carcinomas. Cancer Res. 52:4021-4026. [PubMed]
11. Kensler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD (1987). Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4- methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res. 47:4271-4277. [PubMed]
12. Maltzman TH, Christou M, Gould MN, Jefcoate CR (1991). Effects of monoterpenoids on in vivo DMBA-DNA adduct formation and on phase I hepatic metabolizing enzymes. Carcinogenesis 12:2081-2087. [PubMed]
13. Maltzman TH, Hurt LM, Elson CE, Gould MN (1989). The prevention of nitrosomethylurea-induced mammary tumors by d-limonene and orange peel oil, Carcinogenesis 10:781-783. [PubMed]
14. Mills JJ, Chari RS, Boyer IJ, Gould MN, Jirtle RL (1995). Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. Cancer Res. 55:979-983. [PubMed]
15. Montalto G, Cervello M, Giannitrapani L, Dantona F, Terranova A, Castagnetta LA (2002). Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann. NY Acad. Sci. 963:13-20. [PubMed]
16. Poon GK, Vigushin D, Griggs LJ, Rowlands MG, Coombes RC, Jarman M (1996). Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry. Drug Metab. Dispos. 24:565-571. [PubMed]
17. Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH (2000). Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin. Cancer Res. 6:390-396. [PubMed]
18. Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Marnocha R, Wilding G, Bailey HH (1998). Phase I clinical trial of perillyl alcohol administered daily. Clin. Cancer Res. 4:1159-1164. [PubMed]
19. Roebuck BD, Liu YL, Rogers AE, Groopman JD, Kensler TW (1991). Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res. 51:5501-5506. [PubMed]
20. Sambrook J, Fritsch EF, Maniatis T (1989). Analysis and cloning of eukaryotic genomic DNA. In: Molecular Cloning: A Laboratory Manual, Cold Springs Harbor Lab. Press, 2nd Ed., Plainview, NY pp. 9.1-9.62.
21. Sarin SK, Thakur V, Guptan RC, Saigal S, Malhotra V, Thyagarajan SP, Das BC (2001). Profile of hepatocellular carcinoma in India: An insight into the possible etiologic associations. J. Gastroenterol. Hepatol. 16:666-673. [PubMed]
22. Sparfel L, Langouet S, Fautrel A, Salles B, Guillouzo A (2002). Investigations on the effects of oltipraz on the nucleotide excision repair in the liver. Biochem. Pharmacol. 63:745-749. [PubMed]
23. Vigushin DM, Poon GK, Boddy A, Jarman M, Coombes RC (1998). Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer. Cancer Chemother. Pharmacol. 42:111-117. [PubMed]
24. Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M, Whittle H, Kirk GD, Hall AJ (2000). Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int. J. Cancer 86:1-7. [PubMed]